Search research articles
Contact Us
Filters
Showing results (141-150 of 161) with videos related to
Page
of 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3
Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.
Cancer
|
August 10, 2021
Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation
Erica D Warlick, Celalettin Ustun, Astrid Andreescu, et al.
British Journal of Cancer
|
March 20, 2003
Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen
J Kupryjańczyk, T Szymańska, R Madry, et al.
Nature Medicine
|
September 19, 2017
The N<sup>6</sup>-methyladenosine (m<sup>6</sup>A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells
Ly P Vu, Brian F Pickering, Yuanming Cheng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 11, 2003
P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens
J Plisiecka-Hałasa, G Karpińska, T Szymańska, et al.
Haematologica
|
July 16, 2016
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia
Catherine C Coombs, David A Sallman, Sean M Devlin, et al.
Blood
|
September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza, James A Reeves, Eric J Feldman, et al.
Ginekologia Polska
|
May 11, 2002
[Proposal for delivery in the XXI century]
R Klimek, A Basta, G H Breborowicz, et al.
Cell Stem Cell
|
February 21, 2017
Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia
Andriana G Kotini, Chan-Jung Chang, Arthur Chow, et al.
Nature Communications
|
February 23, 2016
MSI2 is required for maintaining activated myelodysplastic syndrome stem cells
James Taggart, Tzu-Chieh Ho, Elianna Amin, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 161) with videos related to
Sort By:
Page
of 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3
Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.
Cancer
|
August 10, 2021
Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation
Erica D Warlick, Celalettin Ustun, Astrid Andreescu, et al.
British Journal of Cancer
|
March 20, 2003
Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen
J Kupryjańczyk, T Szymańska, R Madry, et al.
Nature Medicine
|
September 19, 2017
The N<sup>6</sup>-methyladenosine (m<sup>6</sup>A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells
Ly P Vu, Brian F Pickering, Yuanming Cheng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 11, 2003
P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens
J Plisiecka-Hałasa, G Karpińska, T Szymańska, et al.
Haematologica
|
July 16, 2016
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia
Catherine C Coombs, David A Sallman, Sean M Devlin, et al.
Blood
|
September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza, James A Reeves, Eric J Feldman, et al.
Ginekologia Polska
|
May 11, 2002
[Proposal for delivery in the XXI century]
R Klimek, A Basta, G H Breborowicz, et al.
Cell Stem Cell
|
February 21, 2017
Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia
Andriana G Kotini, Chan-Jung Chang, Arthur Chow, et al.
Nature Communications
|
February 23, 2016
MSI2 is required for maintaining activated myelodysplastic syndrome stem cells
James Taggart, Tzu-Chieh Ho, Elianna Amin, et al.
Page
of 17